Automate Your Wheel Strategy on SPRO
With Tiblio's Option Bot, you can configure your own wheel strategy including SPRO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SPRO
- Rev/Share 0.7229
- Book/Share 0.5859
- PB 3.1744
- Debt/Equity 0.1101
- CurrentRatio 3.9747
- ROIC -1.1729
- MktCap 104671872.0
- FreeCF/Share -0.5771
- PFCF -3.2373
- PE -1.9133
- Debt/Assets 0.0582
- DivYield 0
- ROE -1.2221
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SPRO | Evercore ISI | Outperform | In-line | -- | $5 | Dec. 20, 2024 |
News
Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The heavy selling pressure might have exhausted for Spero Therapeutics (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results
Published: June 11, 2025 by: Seeking Alpha
Sentiment: Positive
Based on the positive results of the registrational Phase 3 PIVOT-PO study, Tebipenem is expected to be approved under the SPA in mid-2026. Spero will not bear any costs or risks since GSK, as a license partner, will take over commercialization. Approval is expected to trigger in total of $175 million in milestone payments over the next 12 months.
Read More
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.
Read More
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
Published: May 28, 2025 by: Benzinga
Sentiment: Positive
GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy.
Read More
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025.
Read More
About Spero Therapeutics, Inc. (SPRO)
- IPO Date 2017-11-02
- Website https://sperotherapeutics.com
- Industry Biotechnology
- CEO Esther P. Rajavelu
- Employees 32